Differentiating active from stable vitiligo: The role of dermoscopic findings and their relation to CXCL10

• DOI: 10.1111/jocd.14922
• Publication Date: 2022-03-17T16:56:59Z
• Authors: Sarah Ibrahim; Rehab A. Hegazy; Heba I. Gawdat; Samia Esmat; Esraa Mahmoud; Laila Rashed; Amira Aly Hegazy; Dina G. Saadi
• Keywords: Chemokine CXCL10; 03 medical and health sciences; Cross-Sectional Studies; 0302 clinical medicine; Vitiligo; Humans; Dermoscopy; 3. Good health

AbstractBackgroundDistinguishing vitiligo activity/stability status is pivotal in the management of patients with vitiligo. CXCL10 is a chemokine released in the tissues and sera of patients with vitiligo and an indicator of disease activity.AimThis study aimed to assess the role of dermoscopy in detecting active and stable vitiligo by comparing the dermoscopic signs in vitiligo with Vitiligo Disease Activity Score (VIDA), clinical activity, and CXCL10 activity.MethodsNinety‐seven patients with vitiligo were enrolled in this cross‐sectional study. Vitiligo activity/stability was assessed using VIDA scores, clinical examination, dermoscopy, and serum CXCL10 levels measured by enzyme‐linked immunosorbent assay technique. Dermoscopic scores were calculated using BPLeFoSK score.ResultsThe dermoscopic score was concordant with the VIDA score in 83.5% of patients (n = 81), clinical assessment in 97.9% (n = 95), and serum CXCL10 level in 70.1% (n = 68). Dermoscopic signs of ill‐defined border, satellite lesions, and micro‐Koebner and starburst appearance were more common in active vitiligo, while a well‐defined border was more common in stable lesions.ConclusionDermoscopic examination is a practical, reliable, noninvasive, semi‐objective tool in the assessment of vitiligo activity/stability that helps reach an informed decision on the disease status to choose the appropriate therapeutic modality.